Active-ingredient Dossier
Bortezomib
Active-ingredient Dossier for Bortezomib (proteasome inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: DBL
- Brand: BORTEZOMIB EVER PHARMA
- Brand: BORTEZOMIB
- Brand: VELCADE
- Brand: BORTEZOM
- Brand: BORTEZOMIB
- Therapeutic area: Oncology
- Therapeutic area: Haematology
What is Bortezomib Bortezomib is a proteasome inhibitor .
Australian brands containing
Bortezomib — DBL — BORTEZOMIB EVER PHARMA — BORTEZOMIB — VELCADE — BORTEZOMIB — BORTEZOM — BORTEZOMIB — BORTEZOMIB — BORTEZOMIB — BORTEZOMIB — BORTEZOMIB-AFT — APO-Bortezomib
Therapeutic areas
Bortezomib is registered in oncology, with 17 brands on the ARTG .
Sponsor landscape
Bortezomib is marketed by 14 sponsors including Arrotex Pharmaceuticals, Hetero, Eugia Pharma, Pharmacor, Medsurge Pharma, and Baxter Healthcare .
PBS and regulatory activity
One brand containing bortezomib has PBS-listed items, with the latest PBS schedule date of 1 May 2026 . In the 2019–20 financial year, government expenditure on bortezomib was approximately $58.5 million across 43,582 prescriptions . The latest PBAC outcome was recorded on 1 March 2022, with 5 brands having PBAC outcomes on record . The latest AusPAR was published on 2 July 2012, with 1 brand having an AusPAR on record .